-- 木曜日のプレマーケット取引では、テクノロジー株は横ばいからやや上昇し、ステート・ストリートSPDR S&P半導体ETF(XSD)は取引されず、ステート・ストリート・テクノロジー・セレクト・セクターSPDRファンド(XLK)は0.3%上昇した。 台湾積体電路製造(TSM)の株価は、第1四半期の利益と純売上高が増加を発表したにもかかわらず、1%以上下落した。 ガイドワイヤー(GWRE)の株価は、損害保険会社向けの人工知能アシスタントを発表したことを受け、1%以上上昇した。 ジンコソーラー・ホールディングス(JKS)の株価は、第4四半期の純損失が拡大し、売上高が減少したことを受けて、10%近く下落した。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.